39
Participants
Start Date
March 17, 2022
Primary Completion Date
October 26, 2023
Study Completion Date
September 1, 2024
MBG453
Solution for intravenous infusion
Azacitidine
Solution for subcutaneous injection or intravenous administration
Decitabine
Solution for intravenous administration
INQOVI (oral decitabine)
Tablet for oral administration
Tisch Hospital NYU Langone, New York
Duke Cancer Institute, Durham
Advent Health Orlando, Orlando
University Hospitals Of Cleveland, Cleveland
Cleveland Clinic, Cleveland
University Of Michigan, Ann Arbor
Karmanos Cancer Institute, Detroit
Uni Of TX MD Anderson Cancer Cntr, Houston
Texas Oncology San Antonio USO, San Antonio
SCRI-Colorado Blood Cancer Institute, Denver
Mayo Clinic Arizona, Phoenix
Arizona Oncology Associates, Tucson
Yale University School Of Medicine, New Haven
Uni of Massachusetts Medical Center, Worcester
Mount Sinai Medical Center, New York
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY